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Background
Transthyretin (TTR) amyloidosis is a progressive and fatal
systemic disorder caused by misfolded TTR monomers
that cumulatively deposit in the heart, peripheral nerves
and other organ systems. TTR Amyloidosis-associated car-
diomyopathy (ATTR-CM), caused by TTR amyloid infil-
tration of the myocardium and conduction system, results
in a restrictive cardiomyopathy associated with atrial
arrhythmias, progressive heart failure with preserved ejec-
tion fraction in early phases, and leads to reduced life
expectancy. ISIS-TTRRx is a first-in-class, 2nd-generation
antisense oligonucleotide designed to produce substantial
reductions in the levels of both mutant and wild type TTR
produced from the liver.
Methods
We plan to conduct a Phase 3 randomized, double-
blind, placebo-controlled, global study designed to eval-
uate the efficacy and safety of ISIS-TTRRx in patients
with ATTR-CM. The study will evaluate the differences
observed between patients treated with placebo and
with ISIS-TTRRx over 24 months evaluating several key
endpoints. Serum biomarkers including circulating TTR
levels, NT-pro-BNP and troponin, imaging endpoints
including global longitudinal strain by echocardiography,
clinical outcomes including mortality, transplants, cardi-
ovascular hospitalization and arrhythmic events, and
clinical status including New York Heart Association
(NYHA) class, and the patient-reported instrument
Kansas City Cardiomyopathy Questionnaire (KCCQ)
will be evaluated. The trial is designed to enroll approxi-
mately 400 ATTR-CM patients with documented senile
systemic amyloidosis (SSA) or documented familial amy-
loid cardiomyopathy (FAC), including theVal122Ile
mutation and other TTR mutations, in addition to
biopsy-proven amyloid deposits. Patients will be rando-
mized 2:1, ISIS-TTRRx:placebo, with ISIS-TTRRx admi-
nistered subcutaneously at 300 mg every other day for
five days, then weekly for 24 months. The study will
have 85% power to detect a difference between treat-
ment groups in the final primary endpoint, with a signif-
icance level of p < 0.05. All patients completing the
Phase 3 study will be eligible to enroll in a Phase 3
open-label extension study or otherwise receive access
to ISIS-TTRRx. An academic Steering Committee will
oversee trial conduct, an independent Clinical Event
Committee will adjudicate study outcome endpoints,
and an independent Data Safety Monitoring Committee
will periodically review and evaluate accumulated study
data for participant safety and, when appropriate, effi-
cacy, and make recommendations to the sponsor and
Steering Committee concerning the continuation, modi-
fication, or termination of the trial.
Results and conclusions
Results of the trial are anticipated in 2019. The trial will
establish the role of therapy with ISIS-TTRRx. in this
patient population for whom effective treatments to alter
the progression of the disease are needed.
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